Publicacións nas que colabora con Julio Núñez Villota (22)

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

2022

  1. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care

    Expert Opinion on Pharmacotherapy, Vol. 23, Núm. 14, pp. 1589-1599

  2. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  3. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  4. Serum potassium dynamics during acute heart failure hospitalization

    Clinical Research in Cardiology, Vol. 111, Núm. 4, pp. 368-379

2021

  1. Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 765-772

  2. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry

    ESC Heart Failure, Vol. 8, Núm. 1, pp. 95-105

  3. Impact of comorbidities in the decision of using invasive management in elderly patients with NSTEACS

    REC: Interventional Cardiology, Vol. 3, Núm. 1, pp. 15-20

  4. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

  5. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  6. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  7. Prognosis impact of diabetes in elderly women and men with non-st elevation acute coronary syndrome

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  8. Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2020

  1. Beneficio del tratamiento invasivo en ancianos con comorbilidades y síndrome coronario agudo sin elevación del ST

    REC: Interventional Cardiology, Vol. 2, Núm. 4, pp. 315-315

  2. Estimation of the major cardiovascular events prevention with Inclisiran

    Atherosclerosis, Vol. 313, pp. 76-80

  3. Relevancia de la carga de comorbilidades en el manejo invasivo del síndrome coronario agudo en pacientes ancianos

    REC: Interventional Cardiology, Vol. 2, Núm. 4, pp. 316-316

2019

  1. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome

    European Journal of Internal Medicine, Vol. 62, pp. 48-53

  2. Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design

    Revista Espanola de Cardiologia, Vol. 72, Núm. 2, pp. 154-159

2017

  1. Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: The AGTP II trial

    BMJ Open, Vol. 7, Núm. 8